Concentrations of atmospheric carbon dioxide (CO) have continued to increase whereas atmospheric deposition of sulphur and nitrogen has declined in Europe and the USA during recent decades. Using time series of flux observations from 23 forests distributed throughout Europe and the USA, and generalised mixed models, we found that forest-level net ecosystem production and gross primary production have increased by 1% annually from 1995 to 2011. Statistical models indicated that increasing atmospheric CO was the most important factor driving the increasing strength of carbon sinks in these forests. We also found that the reduction of sulphur deposition in Europe and the USA lead to higher recovery in ecosystem respiration than in gross primary production, thus limiting the increase of carbon sequestration. By contrast, trends in climate and nitrogen deposition did not significantly contribute to changing carbon fluxes during the studied period. Our findings support the hypothesis of a general CO-fertilization effect on vegetation growth and suggest that, so far unknown, sulphur deposition plays a significant role in the carbon balance of forests in industrialized regions. Our results show the need to include the effects of changing atmospheric composition, beyond CO, to assess future dynamics of carbon-climate feedbacks not currently considered in earth system/climate modelling.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574890 | PMC |
http://dx.doi.org/10.1038/s41598-017-08755-8 | DOI Listing |
Curr Oncol Rep
January 2025
Medical College of Georgia of the University System of Georgia, 2 Oceans West Blvd, Daytona Beach Shores, FL, 32118, USA.
Background: Disease-focus management of late-stage cancer without addressing patients' preferences or quality of life (QoL) can lead to unsatisfactory patient and disease outcomes.
Methods: A PRISMA-adherent systematic review of the literature was conducted via PubMed, Embase, Scopus, and Google Scholar to assess the current late-stage cancer treatment modality, setting, timing, and cost, their impact on patient and disease outcomes, and possible interventions for improvement.
Results: Out of many studies, twelve from North America, Western Europe, and Asia met our inclusion criteria.
Hellenic J Cardiol
January 2025
Departments of Medicine and of Epidemiology and Population Health, Stanford University School of Medicine; and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA. Electronic address:
Under diverse contributing factors in different scientific micro-environments, the number of authors who publish extreme numbers of full articles in a single year has increased. Cardiology is the subfield that has the largest share of authors with extreme publishing behavior than any other subfield in science (outside physics). Between 2000 and 2022, 137 authors in the subfield of Cardiovascular System (CVS, Science-Metrix classification) have published over 60 full articles in at least one calendar year and are also highly-cited.
View Article and Find Full Text PDFPublic Health
January 2025
Global Brain Health Institute, Trinity College, Dublin, Ireland and University of California, San Francisco, CA, 94158, USA; University of Chicago, Pritzker School of Medicine, Chicago, IL, 60637, USA.
Objective: The topic of brain health across the life-course is currently receiving exponential attention. Alongside this, exposure to lifestyle-related risk factors for Alzheimer's disease and related dementias accumulates across the life-course. This study aimed to explore young adults' (18-39 years) perceptions and understanding of brain health and dementia risk.
View Article and Find Full Text PDFCytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!